BACKGROUND: Currently, first-line chemotherapy in advanced colorectal cancer is not tailored on predictive biomarkers. Bax proapoptotic protein may correlate to chemosensitivity and differential response to irinotecan or oxaliplatin-based combinations. METHODS:Bax expression was assessed by immunohistochemistry in 49 advanced colorectal cancer patients enrolled at our institution from 2002 to 2004 within a multicenter, phase II, randomized trial of first-lineUFT/leucovorin/irinotecan (TEGAFIRI) versus UFT/leucovorin/oxaliplatin (TEGAFOX). RESULTS:Bax-positive and negative samples were 49 and 51 %. Response was significantly lower in Bax positive (25 %) as compared to Bax negative (56 %) (Odds ratio = 0.26; p = 0.03). No significant difference was noted in TEGAFOX subgroup; in TEGAFIRI arm, responses were lower in Bax positive (18 %) than Bax negative (67 %) (Odds ratio = 0.11; p = 0.03). No difference in terms of progression-free and overall survival was observed according to Bax. CONCLUSION: Bax-negative colorectal cancer may identify a specific phenotype of patients with significantly higher chance to respond to doublet irinotecan-based chemotherapy.
RCT Entities:
BACKGROUND: Currently, first-line chemotherapy in advanced colorectal cancer is not tailored on predictive biomarkers. Bax proapoptotic protein may correlate to chemosensitivity and differential response to irinotecan or oxaliplatin-based combinations. METHODS:Bax expression was assessed by immunohistochemistry in 49 advanced colorectal cancerpatients enrolled at our institution from 2002 to 2004 within a multicenter, phase II, randomized trial of first-line UFT/leucovorin/irinotecan (TEGAFIRI) versus UFT/leucovorin/oxaliplatin (TEGAFOX). RESULTS:Bax-positive and negative samples were 49 and 51 %. Response was significantly lower in Bax positive (25 %) as compared to Bax negative (56 %) (Odds ratio = 0.26; p = 0.03). No significant difference was noted in TEGAFOX subgroup; in TEGAFIRI arm, responses were lower in Bax positive (18 %) than Bax negative (67 %) (Odds ratio = 0.11; p = 0.03). No difference in terms of progression-free and overall survival was observed according to Bax. CONCLUSION:Bax-negative colorectal cancer may identify a specific phenotype of patients with significantly higher chance to respond to doublet irinotecan-based chemotherapy.
Authors: P Therasse; S G Arbuck; E A Eisenhauer; J Wanders; R S Kaplan; L Rubinstein; J Verweij; M Van Glabbeke; A T van Oosterom; M C Christian; S G Gwyther Journal: J Natl Cancer Inst Date: 2000-02-02 Impact factor: 13.506
Authors: F Perrone; A Lampis; M Orsenigo; M Di Bartolomeo; A Gevorgyan; M Losa; M Frattini; C Riva; S Andreola; E Bajetta; L Bertario; E Leo; M A Pierotti; S Pilotti Journal: Ann Oncol Date: 2008-07-31 Impact factor: 32.976
Authors: A Paradiso; G Simone; M D Lena; B Leone; C Vallejo; J Lacava; S Dellapasqua; M G Daidone; A Costa Journal: Br J Cancer Date: 2001-03-02 Impact factor: 7.640
Authors: E Bajetta; M Di Bartolomeo; R Buzzoni; L Mariani; N Zilembo; E Ferrario; S Lo Vullo; E Aitini; L Isa; C Barone; S Jacobelli; E Recaldin; G Pinotti; A Iop Journal: Br J Cancer Date: 2007-01-23 Impact factor: 7.640
Authors: J Kupryjańczyk; T Szymańska; R Madry; A Timorek; J Stelmachów; G Karpińska; A Rembiszewska; I Ziółkowska; E Kraszewska; J Debniak; J Emerich; M Ułańska; A Płuzańska; M Jedryka; M Goluda; A Chudecka-Głaz; I Rzepka-Górska; M Klimek; K Urbański; J Breborowicz; J Zieliński; J Markowska Journal: Br J Cancer Date: 2003-03-24 Impact factor: 7.640